NASDAQ:AKTX Akari Therapeutics (AKTX) Stock Price, News & Analysis → Your $200 account credit is about to expire (From MarketBeat) (Ad) Free AKTX Stock Alerts $1.90 +0.04 (+2.15%) (As of 11:32 AM ET) Add Compare Share Share Today's Range$1.85▼$1.9050-Day Range$1.80▼$3.0152-Week Range$1.66▼$5.50Volume1,702 shsAverage Volume10,330 shsMarket Capitalization$10.73 millionP/E RatioN/ADividend YieldN/APrice TargetN/A Stock AnalysisStock AnalysisChartCompetitorsFinancialsHeadlinesOwnershipSEC FilingsShort InterestSocial MediaStock AnalysisChartCompetitorsFinancialsHeadlinesOwnershipSEC FilingsShort InterestSocial Media Get Akari Therapeutics alerts: Email Address Ad DTIWarning: this could blow your mindBuckle up… ‘Cause this might shatter everything you’ve heard about “income trading”. In fact, it’s such an extreme diversion from what most people think of typical income trades that I call it: The Perfect Income Trade You see, most of the income techniques out there target a couple of percent. Maybe 5 - 10 percent if you’re lucky. But this new way of trading income on the world’s top stocks goes after more than 10x that kind of return. And here’s the best news of all: This trade can target an opportunity like that every week. Every single week. Meaning an investor has the chance to “stack up” these more aggressive income trades over and over. If that sounds interesting…Watch the presentation here About Akari Therapeutics Stock (NASDAQ:AKTX)Akari Therapeutics, Plc, a clinical-stage biopharmaceutical company, focuses on developing advanced therapies for autoimmune and inflammatory diseases. Its lead product candidate is nomacopan, a second-generation complement inhibitor that prevents inflammatory and prothrombotic activities, including paroxysmal nocturnal hemoglobinuria, Guillain-Barré syndrome, hematopoietic stem cell transplant-associated thrombotic microangiopathy, and bullous pemphigoid, as well as pre-clinical program developing long-acting PASylated-nomacopan for treatment of geographic atrophy secondary to dry age-related macular degeneration. The company is based in London, the United Kingdom.Read More AKTX Stock Price History View Price History Chart DataSkip Price History Chart 30 days | 90 days | 365 days | Advanced Chart AKTX Stock News HeadlinesMarch 23, 2024 | americanbankingnews.comAkari Therapeutics (NASDAQ:AKTX) Earns Sell Rating from Analysts at StockNews.comMarch 18, 2024 | americanbankingnews.comAkari Therapeutics, Plc (NASDAQ:AKTX) Short Interest UpdateMarch 28, 2024 | Crypto 101 Media (Ad)Altcoin FRENZY Alert…Bitcoin recently crossed the highest price in its 15-year history… Less than 2 years after one of the most vicious crypto market meltdowns we've ever seen! Bitcoin's BOOM also sent shockwaves through the altcoin market, with select coins seeing HUGE moves in a matter of days… Like Fetch.ai, that gained over 350% in just the last 30 days… March 17, 2024 | msn.comPVL: Fifi Sharma, Ced Domingo power Akari romp of NxledMarch 7, 2024 | bizjournals.comPetri Dish: C4’s deal with Merck KGaA; Boston and California biotechs mergeMarch 6, 2024 | stockhouse.comSHAREHOLDER UPDATE: Halper Sadeh LLC Investigates AKTX, HES, TGAN, NSMarch 5, 2024 | businesswire.comAKTX Stock Alert: Halper Sadeh LLC Is Investigating Whether the Merger of Akari Therapeutics, Plc Is Fair to ShareholdersFebruary 27, 2024 | msn.comPVL: Grethcel Soltones, Akari still a work in progressMarch 28, 2024 | Gold Safe Exchange (Ad)Trump’s “Tax Free” Retirement Strategy Since 1924 — over one hundred years — the US dollar has lost nearly 18x its value. In other words, a dollar back then would buy $17.82 worth of goods in today's money. If you're planning on retiring any time soon…This poses a real problem.February 25, 2024 | msn.comPVL: Ced Domingo has a quiet Akari debut as she adjusts to new systemFebruary 24, 2024 | msn.comPVL: Cignal turns back Akari to open All-Filipino bidFebruary 16, 2024 | msn.comEuropean Equities Traded in the US as American Depositary Receipts Set to End Week Higher in Friday TradingFebruary 9, 2024 | msn.comPVL: Akari’s Max Juangco taking pressure of her pro debut in strideFebruary 7, 2024 | msn.comEuropean Equities Traded in the US as American Depositary Receipts Slightly Lower in Wednesday TradingFebruary 2, 2024 | msn.comEuropean Equities Traded in the US as American Depositary Receipts Trend Lower in Friday Trading But End Week HigherJanuary 23, 2024 | investing.comAkari Therapeutics PLC (AKTX)January 22, 2024 | msn.comPVL: Faith Nisperos, Akari Chargers aim for Final FourJanuary 2, 2024 | finanznachrichten.deAkari Therapeutics Plc: Akari Therapeutics Announces Existing Investors Support the Company Through a $2 Million Private Placement FinancingJanuary 2, 2024 | finance.yahoo.comAkari Therapeutics Announces Existing Investors Support the Company Through a $2 Million Private Placement FinancingJanuary 2, 2024 | finance.yahoo.comAkari Therapeutics Announces Existing Investors Support the Company Through a $2 Million Private Placement FinancingDecember 16, 2023 | msn.comAkari Therapeutics Plc - ADR (AKTX) Price Target Increased by 45.45% to 81.60December 14, 2023 | finance.yahoo.comAkari Therapeutics to Present at Biotech Showcase 2024December 2, 2023 | investing.comAkari Therapeutics (AKTX) Earnings Dates & ReportsDecember 1, 2023 | msn.comEuropean Equities Traded in the US as American Depositary Receipts Poised to End Week Flat in Friday TradingNovember 28, 2023 | sg.finance.yahoo.comAkari Therapeutics, Plc (CLA.F)November 24, 2023 | msn.comEuropean Equities Traded in the US as American Depositary Receipts Climb Higher FridayNovember 16, 2023 | finance.yahoo.comAkari Therapeutics Presents Poster on Progress in Pre-Clinical Development of Long-Acting PAS-Nomacopan as a Potential Treatment for Geographic Atrophy at the 4th Annual Dry AMD Therapeutic Development ConferenceSee More Headlines Receive AKTX Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Akari Therapeutics and its competitors with MarketBeat's FREE daily newsletter. Email Address Company Calendar Last Earnings3/31/2020Today3/28/2024Next Earnings (Estimated)5/06/2024Fiscal Year End12/31/2024Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ SectorMedical Industry Pharmaceutical preparations Sub-IndustryN/A Current SymbolNASDAQ:AKTX CUSIPN/A CIK1541157 Webwww.akaritx.com Phone442080040261Fax646-843-9352Employees15Year FoundedN/AProfitability EPS (Most Recent Fiscal Year)N/A Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet IncomeN/A Net MarginsN/A Pretax MarginN/A Return on EquityN/A Return on AssetsN/A Debt Debt-to-Equity RatioN/A Current Ratio1.56 Quick RatioN/A Sales & Book Value Annual SalesN/A Price / SalesN/A Cash FlowN/A Price / Cash FlowN/A Book Value$0.48 per share Price / Book3.92Miscellaneous Outstanding Shares5,650,000Free Float2,159,000Market Cap$10.62 million OptionableNot Optionable Beta1.02 The Best High-Yield Dividend Stocks for 2024Looking to generate income with your stock portfolio? Use these ten stocks to generate a safe and reliable source of investment income.Get This Free Report Key ExecutivesMs. Rachelle Suzanne Jacques (Age 53)President, CEO & Director Comp: $1.38MMs. Wendy F. DiCicco CPA (Age 57)Interim Chief Financial Officer Ms. Melissa Bradford-Klug (Age 54)Chief Operating Officer Dr. Miles Nunn (Age 55)Chief Scientific Officer Dr. John F. Neylan III (Age 71)M.D., Executive VP & Chief Medical Officer Ms. Beth-Anne LangSenior Vice President of Regulatory AffairsAnnie MackFinancial ControllerMore ExecutivesKey CompetitorsMonopar TherapeuticsNASDAQ:MNPRCadrenal TherapeuticsNASDAQ:CVKDASLAN PharmaceuticalsNASDAQ:ASLNNightHawk BiosciencesNYSE:NHWKImunonNASDAQ:IMNNView All CompetitorsInstitutional OwnershipOmnia Family Wealth LLCBought 28,511 shares on 2/5/2024Ownership: 1.551%View All Institutional Transactions AKTX Stock Analysis - Frequently Asked Questions How have AKTX shares performed in 2024? Akari Therapeutics' stock was trading at $3.12 on January 1st, 2024. Since then, AKTX stock has decreased by 39.7% and is now trading at $1.88. View the best growth stocks for 2024 here. Are investors shorting Akari Therapeutics? Akari Therapeutics saw a decrease in short interest in the month of March. As of March 15th, there was short interest totaling 6,000 shares, a decrease of 37.5% from the February 29th total of 9,600 shares. Based on an average trading volume of 9,600 shares, the days-to-cover ratio is presently 0.6 days. Approximately 0.1% of the shares of the stock are sold short. View Akari Therapeutics' Short Interest. When is Akari Therapeutics' next earnings date? The company is scheduled to release its next quarterly earnings announcement on Monday, May 6th 2024. View our AKTX earnings forecast. How were Akari Therapeutics' earnings last quarter? Akari Therapeutics, Plc (NASDAQ:AKTX) issued its quarterly earnings results on Tuesday, March, 31st. The biopharmaceutical company reported ($7.80) earnings per share for the quarter, missing analysts' consensus estimates of ($2.80) by $5.00. When did Akari Therapeutics' stock split? Akari Therapeutics's stock reverse split before market open on Thursday, August 17th 2023. The 1-20 reverse split was announced on Thursday, August 17th 2023. The number of shares owned by shareholders was adjusted after the market closes on Thursday, August 17th 2023. An investor that had 100 shares of stock prior to the reverse split would have 5 shares after the split. What other stocks do shareholders of Akari Therapeutics own? Based on aggregate information from My MarketBeat watchlists, some companies that other Akari Therapeutics investors own include SCYNEXIS (SCYX), Sorrento Therapeutics (SRNE), TherapeuticsMD (TXMD), Biocept (BIOC), OPKO Health (OPK), Anavex Life Sciences (AVXL), Rigel Pharmaceuticals (RIGL), Teva Pharmaceutical Industries (TEVA), Vascular Biogenics (VBLT) and Heat Biologics (HTBX). Who are Akari Therapeutics' major shareholders? Akari Therapeutics' stock is owned by many different institutional and retail investors. Top institutional shareholders include Omnia Family Wealth LLC (1.55%). View institutional ownership trends. How do I buy shares of Akari Therapeutics? Shares of AKTX stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. Compare Top Brokerages Here. This page (NASDAQ:AKTX) was last updated on 3/28/2024 by MarketBeat.com Staff From Our PartnersTop Project Outperforms BTC in 2023…Crypto 101 MediaThis AI Trade Machine Made 1,729%* (With 89% Wins)Prosper Trading Academy“The Stock Market’s Bull Run is Far from Over” -BarronsVertical Research AdvisorySHOCKING Footage From Tesla Gigafactory In Austin, TexasInvestorPlaceBuy this small stock before coming AI Tidal WaveChaikin AnalyticsThe 3rd Revolution in WarfareWeiss RatingsBill Ackman’s 2024 warningPorter & CompanyAI healthcare stock poised for 36,996% growth?Behind the Markets Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Akari Therapeutics, Plc Please log in to your account or sign up in order to add this asset to your watchlist. Get 30 Days of MarketBeat All Access Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your 30-Day Free Trial Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Your Password: or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Choose a Password: Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.